Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma

Phosphatidylinositol-3-kinase (PI3K) inhibitors have shown activity in relapsed or refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). PI3K inhibitors have been hampered by poor long-term tolerability and toxicity, which interfere with continuous use. Umbralisib, a dual inhibitor of PI3Kδ/casein...

Descripción completa

Detalles Bibliográficos
Autores principales: Fowler, Nathan H., Samaniego, Felipe, Jurczak, Wojciech, Ghosh, Nilanjan, Derenzini, Enrico, Reeves, James A., Knopińska-Posłuszny, Wanda, Cheah, Chan Y., Phillips, Tycel, Lech-Maranda, Ewa, Cheson, Bruce D., Caimi, Paolo F., Grosicki, Sebastian, Leslie, Lori A., Chavez, Julio C., Fonseca, Gustavo, Babu, Sunil, Hodson, Daniel J., Shao, Spencer H., Burke, John M., Sharman, Jeff P., Law, Jennie Y., Pagel, John M., Miskin, Hari P., Sportelli, Peter, O'Connor, Owen A., Weiss, Michael S., Zinzani, Pier Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
RAPID COMMUNICATIONS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8148421/
https://www.ncbi.nlm.nih.gov/pubmed/33683917
http://dx.doi.org/10.1200/JCO.20.03433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8148421/
https://www.ncbi.nlm.nih.gov/pubmed/33683917
http://dx.doi.org/10.1200/JCO.20.03433

Ejemplares similares